EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Ketogenic Diet in the Treatment of Malignant Gliomas: A Systematic Review

Michela Persiani iD, Laura Dallolio iD, Alice Masini iD, Yari Longobucco iD, Simona Bertoli iD, Emilia Guberti, Marta Pellizzari iD, Maria Letizia Petroni iD, Federica Valeriani iD, Francesca Gallè iD, Rossella Sacchetti iD

Nutrients · 03.07.2026 · 18 (13) · 2166

DOI: 10.3390/nu18132166 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Nutrients, online erschienen am 03.07.2026. Verfasst von Michela Persiani und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Quality of Life, University of Bologna, 40126 Bologna, Italy. Hauptthemen laut MEDLINE: Diet, Ketogenic, Glioma, Brain Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The Ketogenic Diet (KD) has been proposed as an adjunct to standard therapy for gliomas by targeting tumor glycolysis. We systematically reviewed evidence on KD interventions in patients with glioma across multiple outcomes.

Methods

Following Cochrane guidelines, we searched MEDLINE, Embase, and Cochrane Library (until 1 February 2025) for studies on humans with glioma treated with any KD versus usual care or other diets. Outcomes included overall survival (OS) and progression-free survival (PFS), quality of life (QoL), biochemical markers (glucose, ketones, glucose–ketone index GKI), anthropometric measures, safety, and tolerability. All study designs were eligible. The quality of the studies was assessed with JBI tools. Data were narratively synthesized due to heterogeneity. The PROSPERO registration is CRD42024547388.

Results

Twenty-three studies (306 patients) were included: two RCTs, 11 quasi-experimental studies, six case series, and four case reports. Dietary interventions included classic KD, modified KD, medium-chain triglyceride KD, and Modified Atkins Diet, sometimes combined with fasting. The overall dropout was 20.3%, mainly due to dietary restrictiveness, disease progression, adverse effects, or QoL concerns. Survival results were inconsistent: RCTs showed no significant OS/PFS differences versus controls, although exploratory analyses suggested better outcomes with lower glucose levels. Ketosis was commonly achieved; glucose reductions were variable, and GKI was rarely reported, with target values seldom reached outside fasting periods. Weight/BMI generally decreased modestly or remained stable; adverse events were mostly mild and tolerability was acceptable.

Conclusions

Evidence for KDs in glioma patients is heterogeneous and limited. Although ketosis and safety are achievable, survival or QoL benefits remain unproven. Given the methodological challenges, the clinical complexity, and the promising potential of the Ketogenic Diet, further well-designed studies are needed to clarify its clinical utility in glioma treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diet, KetogenicGliomaBrain NeoplasmsHumansQuality of LifeTreatment OutcomeFemaleMale

Stichwörter der Autor:innen

gliomaketogenic dietoverall survivalquality of lifesafetytolerability

Autor:innen und Institutionen

  • Department of Quality of Life, University of Bologna, 40126 Bologna, Italy.
  • Department of Biomedical and Neuromotor Sciences DIBINEM, University of Bologna, 40126 Bologna, Italy.
  • Department of Translational Medicine, University of Eastern Piedmont, 28100 Novara, Italy.
  • Department of Health Sciences, University of Florence, 50121 Florence, Italy.
  • Department of Food, Environmental and Nutritional Sciences, University of Milan, 20122 Milan, Italy.
  • Istituto Auxologico Italiano IRCCS, Obesity Unit and Laboratory of Nutrition and Obesity Research, Department of Endocrine and Metabolic Diseases, 20145 Milan, Italy.

ORCID-Profile: Michela Persiani, Laura Dallolio, Alice Masini, Yari Longobucco, Simona Bertoli, Marta Pellizzari, Maria Letizia Petroni, Federica Valeriani, Francesca Gallè, Rossella Sacchetti

Zitieren

APA

Persiani, M., Dallolio, L., Masini, A., Longobucco, Y., Bertoli, S., Guberti, E., Pellizzari, M., Petroni, M. L., Valeriani, F., Gallè, F., & Sacchetti, R. (2026). Ketogenic Diet in the Treatment of Malignant Gliomas: A Systematic Review. Nutrients, 18(13), 2166. https://doi.org/10.3390/nu18132166

Vancouver

Persiani M, Dallolio L, Masini A, Longobucco Y, Bertoli S, Guberti E, et al. Ketogenic Diet in the Treatment of Malignant Gliomas: A Systematic Review. Nutrients. 2026;18(13):2166. doi:10.3390/nu18132166

BibTeX
@article{Persiani2026,
  author = {Persiani, Michela and Dallolio, Laura and Masini, Alice and Longobucco, Yari and Bertoli, Simona and Guberti, Emilia and Pellizzari, Marta and Petroni, Maria Letizia and Valeriani, Federica and Gallè, Francesca and Sacchetti, Rossella},
  title = {Ketogenic Diet in the Treatment of Malignant Gliomas: A Systematic Review},
  journal = {Nutrients},
  year = {2026},
  volume = {18},
  number = {13},
  pages = {2166},
  doi = {10.3390/nu18132166}
}
Kostenlos starten →